Daniel Rabinowitz, the Secretary and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), recently sold a significant portion of his holdings in the company. The sale comes as Natera’s stock trades near its 52-week high of $177, having delivered an impressive 177.73% return over the past year. With a market capitalization of $23.14 billion, the company maintains a GOOD financial health score according to InvestingPro analysis. According to a filing with the Securities and Exchange Commission, Rabinowitz sold 6,223 shares of common stock on January 8, 2025. The shares were sold at a weighted average price of $175.3015, generating a total of approximately $1,090,901.
This transaction was executed as part of a pre-arranged trading plan under Rule 10b5-1, which Rabinowitz adopted on June 14, 2024. Following the sale, Rabinowitz retains direct ownership of 199,804 shares in the company.
In other recent news, Natera Inc (NASDAQ:). has broadened its patent infringement lawsuit against NeoGenomics (NASDAQ:) over the RaDaR assay, a test for molecular residual disease. The company has reported a record Q3 revenue of $439.8 million, marking a 64% increase year-over-year, and conducted 137,000 oncology tests, a 54% increase from the previous year. Amid these developments, TD Cowen, Baird, and Jefferies maintained favorable ratings on Natera’s stock and raised their price targets.
Natera also faced a setback in a false advertising lawsuit against Guardant Health (NASDAQ:), but plans to request the court to overturn the ruling. Additionally, the company has amended an agreement with Dr. Rabinowitz, the Executive Chairman, to continue his role with conditions outlined in the agreement.
These recent developments provide investors with insights into Natera’s current status. The company continues to reinforce its position in the genetic testing industry, despite facing legal challenges and a competitive landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
